文献速递淋巴瘤白血病造血干细胞移植与细胞治疗

CAR T细胞治疗中氟达拉滨年龄调整剂量用于淋巴细胞清除的临床试验模拟研究

Age-adjusted dosing of fludarabine for lymphodepletion in CAR T-cell therapy: a clinical trial simulation study.
PubMed 文献 · Blood Adv · 2025-01-01

本研究利用建模与模拟(含临床试验模拟),基于已发表儿童人群的氟达拉滨药代动力学及其与总生存和累积复发率的关系,评估固定剂量、年龄调整剂量及治疗药物监测剂量方案。模拟显示年龄调整或治疗药物监测剂量可提高目标累积曲线下面积范围内的个体比例,并可能改善临床结局。

要点

  • 氟达拉滨药代动力学呈年龄依赖性,年幼儿童清除率更高。
  • 年龄调整或治疗药物监测剂量较固定剂量提高目标暴露范围内个体比例。
  • 模拟显示年龄调整或治疗药物监测剂量可能改善总生存并降低累积复发率。

核心结论

  • 模拟研究支持使用氟达拉滨年龄调整或治疗药物监测剂量,以增加达到目标暴露范围的个体数量并可能改善临床结局。

研究设计与样本

  • 建模与模拟研究,包括临床试验模拟,氟达拉滨药代动力学及与总生存和累积复发率的关系源自已发表儿童人群。

主要发现

  • 临床试验模拟显示,在儿童年龄范围内,达到目标累积曲线下面积范围(13.8至25 mg×h/L)的个体比例中位数从固定剂量的22%至61%提高至年龄调整剂量的72%和治疗药物监测剂量的94%。
  • 临床试验模拟显示,与固定剂量相比,年龄调整或治疗药物监测剂量可使24个月时总生存的个体数量中位数增加67%,并使12个月时累积复发率的个体数量中位数降低72%。

关键数值与推荐

  • 氟达拉滨目标累积曲线下面积范围定义为13.8至25 mg×h/L。
  • 模拟中考虑的四种氟达拉滨剂量为:75或120 mg/m2累积固定剂量、年龄调整剂量、基于治疗药物监测的剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fludarabine (FLU) is used for lymphodepletion and improves the persistence and expansion of chimeric antigen receptor (CAR) T cells in vivo. Higher FLU systemic exposure is associated with lower relapse risk and improved leukemia-free survival in pediatric patients with acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy. FLU pharmacokinetics (PKs) is age dependent, with increased clearance in younger children. Here, we used modeling and simulation, including clinical trial simulations, to define age-adjusted FLU dosage regimens that may maintain effective FLU exposures and improve outcomes. The FLU PK and pharmacodynamic relationships with overall survival (OS) and cumulative incidence of relapse (CIR) were derived from published pediatric populations. Four FLU dosages were considered for the simulations: 75 or 120 mg/m2 cumulative fixed dose, age-adjusted dosing, and doses based on therapeutic drug monitoring (TDM). The target FLU cumulative area under the curve range was defined as 13.8 to 25 mg × h/L. Clinical trial simulations showed that across the pediatric age range, the number of individuals in the target range increased from a median of 22% to 61% with fixed dosages, to 72% with age-adjusted dosing and 94% with TDM. Clinical trial simulations also showed that age-adjusted or TDM dosing could increase the median number of individuals with OS at 24 months by 67% and decrease the median number of individuals with CIR at 12 months by 72%, compared with fixed dosages. In conclusion, these simulation studies support using FLU age-adjusted or TDM dosing to increase the number of individuals achieving exposure within the targeted range and, therefore, improve clinical outcomes.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Panetta JC, Talleur AC, Naik S, et al. Age-adjusted dosing of fludarabine for lymphodepletion in CAR T-cell therapy: a clinical trial simulation study. Blood Adv. 2025. PMID: 40609087. doi:10.1182/bloodadvances.2025015928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。